-
ACCESS Newswire
|
08:42 AM EDT
TURKU, FI / ACCESS Newswire / May 28, 2026 / Faron Pharmaceuticals, a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board has resolved, based on the authorisation granted by the General Meeting held on 4 May 2026, to issue 8,000,000 additional Special Rights in connection with the First and Second Tranche of Bonds.
In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.
Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
|
Log In Required
Publication Date